1STEINBERG D, WITZTUM J L. Inhibition of PC- SK9:a powerful weapon for achieving ideal LDL cholesterol levels [ J ]. Proc Natl Acad Sci USA, 2009,106 (24) :9546 - 9547.
2NORATA G D, BALLANTYNE C M, CATAPANO A L. New therapeutic principles in dyslipidaemia: fo- cus on LDL and Lp (a) lowering drugs [ J ]. Eur Heart J,2013,34(24) :1783 - 1789.
3REINER ., CATAPANO A L, de BACKER G, et al. ESC/EAS guidelines for the management of dys- lipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiolo- gy (ESC) and the European Atherosclerosis Society (EAS) [ J]. Eur Heart J, 2011,32 ( 14 ) : 1769 - 1818.
4BROWN M S, GOLDSTEIN J L. Biomedicine. Low- ering LDL--not only how low,but how long? [J]. Science,2006,311 : 1721 - 1723.
5TALL A R. Protease variants, LDL, and coronary heart disease [ J ]. N Engl J Med, 2006,354 ( 12 ) : 1310.
6HOOPER A J, BURNETr J R. Anti-PCSK9 thera- pies for the treatment of hypercholesterolemia [ J ]. Expert Opin Biol Ther,2013,13 (3) :429 -435.
7CARIOU B,le MAY C, COSTET P. Clinical aspects of PCSK9 [ J ]. Atherosclerosis ,2011,216 ( 2 ) : 258 - 265.
8MULLARD A. Cholesterol-lowering blockbuster can- didates speed into phase Ill trials[ J ]. Nat Rev Drug Discov ,2012,11 ( 11 ) :817 - 819.
9CRUNKHORN S. Trial watch: PCSK9 antibody re- duces LDL cholesterol [ J ]. Nat Rev Drug Discov, 2012,11(1) :11.
10SEIDAH N G, BENJANNET S, WICKHAM L, et al. The secretory proprotein convertase neural apop- tosis-regulated convertase 1 (NARC-1) :liver regen- eration and neuronal differentiation [ J ]. Proc Natl Acad Sci USA,2003,100 ( 3 ) :928 - 933.
